CCX282-B: Clinical Trials

7 trials of CCX282-B, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

4 completed, 3 terminated. 4 Phase 3, 3 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	4	Terminated 3, Completed 1
Phase 2	3	Completed 3

Follow CCX282-B: new trials by email Literature Review of CCX282-B trials Research Report on CCX282-B

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease GSK1605786A - Crohn's Disease	Phase 3	Terminated	GlaxoSmithKline	255	2011-11-11	2018-01-29
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease GSK1605786A, Placebo - Crohn's Disease	Phase 3	Terminated	GlaxoSmithKline	229	2011-05-09	2017-09-07
Open-Label Extension Study of GSK1605786A GSK1605786A - Crohn's Disease	Phase 3	Terminated	GlaxoSmithKline	399	2011-04-01	2017-09-14
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease GSK1605786A, Placebo - Crohn's Disease	Phase 3	Completed	GlaxoSmithKline	608	2010-12-20	2017-09-19
A Phase II Study of CCX282-B in Patients With Celiac Disease CCX282-B, Placebo - Celiac Disease	Phase 2	Completed	Amgen	90	2007-10-01	2025-03-06
A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease CCX282-B - Crohn's Disease	Phase 2	Completed	Amgen	436	2006-03-01	2025-03-06
Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease CCX282-B - Crohn Disease	Phase 2	Completed	Amgen	70	2004-08-01	2025-03-06

Conditions studied

Sponsors

Countries

Results publications